Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: Atumelnant, Carbamazepine, Midazolam, Digoxin, Metformin; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hip Fractures, Anesthesia, Spinal, Anesthesia, General, Neuromuscular Blockade
Interventions: Rocuronium, Sugammadex, Normal saline; Drug
Lead sponsor: Loyola University; Other
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Pregnancy Termination in Second Trimester
Interventions: Nitrous Oxide, IV Saline; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Denver, Colorado • Albuquerque, New Mexico

Conditions: Sedation, Interventional Radiology, Biopsy, Drainage Procedure
Interventions: ketamine, fentanyl, Midazolam; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 90 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Healthy Participants
Interventions: BBT-877, Midazolam, Itraconazole, Esomeprazole; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Transgender Persons
Interventions: Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet, Midazolam Injectable Solution; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Delirium, Lumbar Radiculopathy, Lumbar Osteoarthritis, Lumbar Spine Disc Degeneration
Interventions: Light sedation with propofol, Induction with propofol, Maintenance anesthetic using a volatile anesthetic, Muscle relaxant during maintenance anesthesia, Pain control with fentanyl, Bispectral Index (BIS) monitoring for depth of anesthesia, Spinal Anesthesia, Midazolam administered during spinal anesthesia, Cerebrospinal fluid collection, Administration of intrathecal morphine; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Surgery, Aging
Interventions: Peer Comparison Feedback, Patient Informational Letter; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older
Enrollment: 517,611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pain, Nausea
Interventions: ropivacaine, Lidocaine/Ketamine, placebo; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Mayfield Heights, Ohio

Conditions: Laceration of Skin
Interventions: Ketamine, Midazolam and fentanyl; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 6 Months to 10 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Cardiac Arrest, Hypothermia
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 9
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Louisville, Kentucky + 6 more

Conditions: Healthy Participants
Interventions: Afimetoran, Phenytoin, Midazolam; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ventricular Tachycardia
Interventions: Versed, Fentanyl, Propofol, Sevoflurane; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: PF-04171327 25 mg, Midazolam 2 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Glycine Transporter-1 inhibitor; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Glendale, California • Bellaire, Texas

Conditions: Sedation
Interventions: Dexmedetomidine load, Ketamine load, Midazolam load, Fentanyl load, Dexmedetomidine maintenance, Ketamine maintenance, Midazolam demand, Fentanyl demand, Benadryl demand; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: Pf-05175157, placebo, midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Metastatic Breast Cancer
Interventions: LY3295668 Erbumine, Endocrine therapy, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Duarte, California • Boston, Massachusetts • San Antonio, Texas

Conditions: Sleep
Interventions: Dexmedetomidine, Propofol, Midazolam, Fentanyl, Isoflurane; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteers
Interventions: E2086; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Breast Cancer
Interventions: Paravertebral Block, Propofol, Fentanyl, Ropivacaine, Midazolam; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene, midazolam; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Healthy Volunteer, Cystic Fibrosis
Interventions: PTI-801, Placebo, PTI-808; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more

Conditions: Renal Insufficiency
Interventions: Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Search by objective public record fields.

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture

Nitrous Oxide Versus Intravenous Sedation for Anesthesia

Evaluation of Ketamine/Midazolam Sedation vs. Fentanyl/Midazolam Sedation for Image-Guided Percutaneous Procedures in Interventional Radiology

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

Effect of Estrogen Treatment on Drug Metabolism and Transport

Shaping Anesthetic Techniques to Reduce Post-operative Delirium

De-adopting Routine Preoperative Benzodiazepines for Older Surgical Patients

Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain

IN Ketamine vs IN Midazolam and Fentanyl for Laceration Repair

Hypothermia's Impact on Pharmacology

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia

A Midazolam Drug Interaction Study With PF-04171327

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

Alternative Sedation During Bronchoscopy

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Effect of Dexmedetomidine Upon Sleep Postoperatively

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)